Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

HIVPreventionPregnancy

Interventions

DRUG

FTC/TDF 200mg/300mg

Standard Dose

DRUG

FTC/TDF 300mg/450mg

150% Standard Dose

DRUG

FTC/TDF 400mg/600mg

200% Standard Dose

Trial Locations (2)

Bwaila District Hospital, Lilongwe

Seke North CRS, Harare

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of North Carolina, Chapel Hill

OTHER

NCT06435026 - Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 | Biotech Hunter | Biotech Hunter